NCT04887935View on ClinicalTrials.gov

Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 4, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Prostate CancerCancer of Prostate
Interventions
DRUG

Dapagliflozin

-The 10 mg dose is reflective of current clinical practice for diabetes and heart failure

Trial Locations (1)

63110

RECRUITING

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

The Foundation for Barnes-Jewish Hospital

OTHER

lead

Washington University School of Medicine

OTHER